Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Comment by lscfaon Mar 26, 2021 2:30pm
155 Views
Post# 32887557

RE:RE:RE:RE:RE:RE:Shareprice

RE:RE:RE:RE:RE:RE:Shareprice0.2% 1067 does not work as a skin lightener. That's why R+F is using it as a spot reducer. Maybe 0.4% 1067 will lighten skin.

"TFC1067 and 2% hydroquinone produced statistically significant skin lightening after 8 weeks of use, but only hydroquinone lightened the normal skin. This pattern continued into week 12 where both products significantly lightened dyschromic skin, but hydroquinone also lightened the normal skin, which is not always desirable."

https://onlinelibrary.wiley.com/doi/10.1111/jocd.13771




MirrorWorldMan wrote: The 15 ml size tube for spot correction only is the real surprise.  The price would be 6x higher if it was in 100ml sizes as we all thought initially upon signing of the R + F deal.  Everyones prior estimate on tube sizes and sales relied on the assumption that 1067 was going to be used in larger tubes for overall lightening,  not as a touch up.  We can only hope that these end users start smearing across their entire face and see the results and order more smaller tubes, or a larger size is offered for general lightneing.  The revised sales forcecasts based upon the smaller tube sizes may be why the share price is in the sewer post news.  More partners in bigger markets for general skin  lightening will propel things.   Yes, this spot correction idea gets us used, we can only anticipate in leads to wider indication through its sales cycle.


<< Previous
Bullboard Posts
Next >>